Opinion

Video

Approved Therapies for Steroid-Refractory Chronic GvHD

Author(s):

Hana Safah, MD,Corey S. Cutler, MD, MPH, FRCPC

Hematologist-oncologists give an overview of the 3 approved treatment options for patients with steroid-refractory chronic GvHD—ruxolitinib, ibrutinib, and belumosudil—and highlight the REACH3 and ROCKstar studies.

Related Videos
Bradley McGregor, MD,
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
3 experts are featured in this series.
Naval G. Daver, MD,
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Systemic Mastocytosis | © สุพัฒตรา แสนพลี – stock.adobe.com
January 17th 2025

Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

US FDA
January 16th 2025

Tabelecleucel BLA Receives FDA CRL in Pretreated EBV+ Post-Transplant Lymphoproliferative Disease

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Erica L. Mayer, MD, MPH
January 13th 2025

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

Naseema Gangat, MBBS, of Mayo Clinic
January 13th 2025

Advances in PV Management Increase Hepcidin Levels and Improve Disease Burden